NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

April 9, 2024

https://www.prnewswire.com/news-releases/neurosense-collaborates-with-lonza-to-identify-exosome-based-biomarkers-in-order-to-advance-neurodegenerative-disease-treatments-and-diagnostics-302111745.html

BASEL, Switzerland and CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ — Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. 

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.